chufangao/CTO huggingface dataset:
Clinical trial NCT05308602: A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
Official title: A Randomized, Double-blinded, Active-controlled Phase II Clinical Study to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥12 Years and Previously Unvaccinated
Sponsor: Sinocelltech Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: There was not a need any more.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-04-01
Primary completion date: 2022-08-01
Completion date: 2023-08-01
Clinical trial NCT05161533: Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
Official title: CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-19
Primary completion date: 2024-10-01
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03086395: Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Official title: Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding Unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-01
Primary completion date: 2018-01-01
Completion date: 2021-01-01
Clinical trial NCT03834220: Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Official title: A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
Sponsor: Debiopharm International SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to lower antitumor activity than expected
Enrollment: 63.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-22
Primary completion date: 2020-12-31
Completion date: 2022-01-04
Baseline population: Intent-to-treat (ITT) Population consisted of all participants who received study drug.
Limitations and caveats: Limitations of the trial such as small numbers of participants analyzed or technical problems leading to unreliable data.~Due to the premature termination of participant recruitment and shortened follow-up, the primary efficacy analysis was likely underpowered in the final analysis, leading to greater statistical uncertainty in results.
Plan to share individual participant data: NO
Clinical trial NCT05098067: Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Official title: Trial of Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy: A Pilot Investigation
Sponsor: Women and Infants Hospital of Rhode Island (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-24
Primary completion date: 2022-10-17
Completion date: 2023-03-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04203537: Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)
Official title: A Two-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics and Preliminary Efficacy Study of CA-008 in Patients Undergoing Total Knee Arthroplasy
Sponsor: Concentric Analgesics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 193.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-04
Primary completion date: 2020-10-26
Completion date: 2020-10-26
Baseline population: 1 subject was randomized to CA-008 60 mg, but actually received placebo~1 subject was randomized to CA-008 36 mg, but actually received placebo~Both subjects are included in the placebo arm
Plan to share individual participant data: NO
Clinical trial NCT02790138: A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)
Acronym: EARNEST
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 102.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-12
Primary completion date: 2020-06-11
Completion date: 2021-02-02
Baseline population: Full Analysis Set included all randomized participants who received at least 1 dose of study medication, as randomized.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT01754857: Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Official title: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-11-12
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Clinical trial NCT04348006: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Official title: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Acronym: MM
Sponsor: Al-Rasheed University College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No patients were enrolled in the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-01
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04352075: Intra Articular Injection of Microfat and PRP in Knee Osteoarthritis
Official title: Intra Articular Injection of Autologous Microfat and Platelet-rich Plasma in the Treatment of Knee Osteoarthritis: a Pilot Study
Acronym: MICROPREP
Sponsor: Clinique Juge (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-15
Primary completion date: 2019-08-01
Completion date: 2020-03-01
Plan to share individual participant data: NO
IPD sharing description: Publication
Clinical trial NCT04102436: Non-Viral TCR Gene Therapy
Official title: A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficulty with availability of GLP-grade reagents for manufacturing.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-03-08
Primary completion date: 2024-03-08
Completion date: 2024-03-08
Plan to share individual participant data: YES
IPD sharing description: .All IPD recorded in the medical record will be shared with intramural investigators upon request.
IPD time frame: Clinical data available during the study and indefinitely.
IPD access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
Clinical trial NCT04549376: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo
Official title: Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial
Acronym: VEP-COV
Sponsor: Bangladesh Reference Institute of Chemical Measurements (BRICM) (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 7.0
Start date: 2020-07-01
Primary completion date: 2020-10-20
Completion date: 2020-10-30
Plan to share individual participant data: YES
IPD sharing description: After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.
IPD time frame: 6 months
IPD access criteria: Available on public domain like figshare, researchgate and others
Clinical trial NCT04837807: Digital Device Users Who Are Treated With Systane Hydration PF
Official title: Understanding Quality of Life in High Digital Device Users Who Are Treated With Systane Hydration PF
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-18
Primary completion date: 2021-11-19
Completion date: 2021-11-19
Plan to share individual participant data: NO
Clinical trial NCT04170023: Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
Official title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-16
Primary completion date: 2023-04-27
Completion date: 2024-03-20
Baseline population: Full analysis set included all participants who received at least 1 dose of ALXN2050 in this study.
Plan to share individual participant data: YES
IPD sharing description: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Clinical trial NCT05032118: Pilot Study of Ketamine Sedation for Aneurysmal Subarachnoid Hemorrhage
Official title: A Pilot Study of Ketamine Sedation Initiated Early After Aneurysmal Subarachnoid Hemorrhage: Effect on Vasospasm, Delayed Cerebral Ischemia, and Functional Outcomes
Acronym: PENDULUM
Sponsor: Oregon Health and Science University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Institution change, no IRB approval
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-27
Primary completion date: 2023-04-27
Completion date: 2023-04-27
Plan to share individual participant data: NO
Clinical trial NCT00659776: MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
Official title: Multi-Disciplinary Study: Magnetic Resonance, Histologic And Electron Microscopy Imaging Of Intravenous Superparamagnetic Crystalline Particles (Ferumoxytol) In CNS Inflammation
Sponsor: Oregon Health and Science University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to staffing shortages and lack of funding during Covid.
Enrollment: 255.0 (ACTUAL)
Number of arms: 3.0
Start date: 2004-07-31
Primary completion date: 2020-12-31
Completion date: 2021-12-31
Baseline population: The study was terminated early due to Covid and funding shortages. Therefore, subject enrollment was not met, and no subjects were enrolled in group 3.
Clinical trial NCT03659136: The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Official title: XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 103.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-28
Primary completion date: 2021-08-30
Completion date: 2022-05-11
Baseline population: Randomised Set (RS): The randomised set included all randomised patients, regardless of whether they received treatment or not.
Plan to share individual participant data: YES
IPD sharing description: Once the criteria in section Time Frame are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Clinical trial NCT04570501: Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
Official title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Discontinuation of drug candidates
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-02-28
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Plan to share individual participant data: NO
Clinical trial NCT02647255: Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Official title: Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)
Acronym: RESCUE
Sponsor: Peking University First Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-31
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Clinical trial NCT05156658: Pharmacokinetic Interactions of ENG Subdermal Implants With Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)
Official title: Pharmacokinetic Interactions of Etonogestrel (ENG) Subdermal Implants With Long-Acting (LA) Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) in Participants of Reproductive Potential
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Protocol's question was answered elsewhere and very low site interest in the trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-01
Primary completion date: 2024-08-02
Completion date: 2024-08-02
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie results in the publication, after deidentification.
IPD time frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
IPD access criteria: * With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.~* For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.~* By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group Data Request form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Clinical trial NCT04969991: Study of Varespladib in Patients Hospitalized With Severe COVID-19
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2
Acronym: STAIRS
Sponsor: Ophirex, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Part 2 of the study was paused on 03-May-2022 due to slow enrollment following low infection rates and hospitalizations of patients with severe COVID-19, and did not recommence prior to study closure (early termination) on 22-Nov-2022.
Enrollment: 18.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-06-30
Primary completion date: 2022-02-11
Completion date: 2022-11-22
Plan to share individual participant data: NO
Clinical trial NCT04456998: GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Sponsor: Gossamer Bio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 86.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-12
Primary completion date: 2022-10-17
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT04222842: CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
Official title: Phase I Study of CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
Sponsor: AnewPharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Day is not required for Anticipated dates.
Enrollment: 96.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2019-12-18
Primary completion date: 2021-12-30
Completion date: 2021-12-30
Clinical trial NCT04163900: Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
Official title: A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer
Sponsor: NuCana plc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve its primary objective of improving overall survival. Based on the IDMC's recommendation, NuCana has closed the study.
Enrollment: 773.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-24
Primary completion date: 2022-03-02
Completion date: 2022-04-05
Baseline population: Intent-to-treat
Limitations and caveats: At Interim Analysis 1, the futility boundary for OS was crossed and the study was closed on 02 Mar 2022. Following study closure, data from the 05 April 2022 final data cut-off (30 day follow-up post the last patient last visit) were analysed. In general, the analyses performed on this final database were those that were scheduled to take place at Interim Analysis 2. However, any p-values or CIs obtained are only viewed as descriptive as the study was stopped for futility.
Plan to share individual participant data: NO
Clinical trial NCT03471507: Bonipar for Acute and Chronic Musculoskeletal Pain
Official title: Efficacy of a Topical Pain Relief Spray Containing Herbal Oil Extracts (Bonipar) Among Individuals With Acute and Chronic Musculoskeletal Pain
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 164.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2022-09-22
Completion date: 2022-09-22
Clinical trial NCT02774005: Study to Assess the Efficacy and Safety of Raxone in LHON Patients
Official title: External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Acronym: LEROS
Sponsor: Santhera Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 199.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-05-31
Primary completion date: 2021-03-29
Completion date: 2021-03-29
Baseline population: A total of 199 patients were enrolled in the study. 198 received treatment and were included in the Safety Population. There were 196 patients in the ITT population. A total of 181 patients were included in the mITT population.
Clinical trial NCT03692221: Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease
Official title: Percutaneous Image Guided Delivery of Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Symptomatic Degenerated Intervertebral Disc Disease
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Stalled due to Covid
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-30
Primary completion date: 2021-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04530487: Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Official title: A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients with High Risk Solid Tumors
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI Request
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-19
Primary completion date: 2024-08-26
Completion date: 2024-08-26
Clinical trial NCT04096716: Mapping Draining Lymph Nodes in CNS Malignancies
Official title: Mapping Draining Lymph Nodes in CNS Malignancies
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient funding/staff
Enrollment: 14.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-12-03
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Plan to share individual participant data: NO